{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:11:29Z","timestamp":1778868689099,"version":"3.51.4"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China Red Cross Foundation Medical Empowerment Public Welfare Special Fund 2024 Pain Innovation Action Clinical Research Project"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>G protein-biased mu-opioid receptor (MOR) agonists such as oliceridine and tegileridine were developed to reduce opioid-related side effects while keeping analgesic efficacy. The US FDA approved oliceridine in 2020 and China NMPA approved tegileridine in January 2024. Clinical development mainly focused on respiratory depression and gastrointestinal problems, but little attention has been paid to the autonomic nervous system (ANS) effects of these drugs. Traditional opioids change heart rate variability (HRV) and sympathovagal balance mainly through central mechanisms. It is not clear whether biased agonists show different autonomic profiles compared with traditional opioids. There is an ongoing scientific debate about whether the benefits of these drugs come from true signaling bias or from low intrinsic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We will conduct a scoping review following JBI methodology and report according to PRISMA-ScR guidelines. We will search PubMed, Embase, Web of Science and Cochrane Library from database start to March 2026. FDA and NMPA regulatory documents will also be searched. Two reviewers will screen studies and extract data independently. We will include in vitro cellular assays, in vivo animal experiments, and clinical studies examining oliceridine, tegileridine or other biased MOR agonists that report cardiovascular or autonomic outcomes. Results will be organized in an Evidence Matrix by drug, evidence level and measurement timepoint. Animal studies will be stratified by anesthetic state (conscious versus anesthetized).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We will map the evidence against three mechanistic paradigms: that biased agonism preserves autonomic homeostasis; that observed benefits come from partial agonism rather than signaling bias; or that no meaningful autonomic differences exist between biased and traditional agonists. This review will map evidence gaps and inform future clinical trial design with autonomic endpoints. We note that tegileridine has much less published data than oliceridine, and this gap analysis will help set research priorities.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Protocol registration:<\/jats:bold>\n                      Open Science Framework (OSF) [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.17605\/OSF.IO\/N2XZC\" xlink:type=\"simple\">https:\/\/doi.org\/10.17605\/OSF.IO\/N2XZC<\/jats:ext-link>\n                      ].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349596","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:31:57Z","timestamp":1778866317000},"page":"e0349596","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autonomic nervous system modulation by G protein-biased mu-opioid receptor agonists: A translational scoping review protocol"],"prefix":"10.1371","volume":"21","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haishan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-0373","authenticated-orcid":true,"given":"Yukai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"2","key":"pone.0349596.ref001","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"T Kenakin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"5449","key":"pone.0349596.ref002","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"LM Bohn","year":"1999","journal-title":"Science"},{"issue":"6813","key":"pone.0349596.ref003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"LM Bohn","year":"2000","journal-title":"Nature"},{"issue":"3","key":"pone.0349596.ref004","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"KM Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"pone.0349596.ref005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"SM DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"7619","key":"pone.0349596.ref006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"A Manglik","year":"2016","journal-title":"Nature"},{"issue":"6","key":"pone.0349596.ref007","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-024-02033-4","article-title":"Tegileridine: first approval","volume":"84","author":"S Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"13","key":"pone.0349596.ref008","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"A Kliewer","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0349596.ref009","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"A Kliewer","year":"2019","journal-title":"Nat Commun"},{"issue":"625","key":"pone.0349596.ref010","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"A Gillis","year":"2020","journal-title":"Sci Signal"},{"issue":"18","key":"pone.0349596.ref011","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/acs.biochem.1c00466","article-title":"Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists","volume":"61","author":"EL Stahl","year":"2022","journal-title":"Biochemistry"},{"issue":"6","key":"pone.0349596.ref012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40263-025-01172-w","article-title":"Opioid analgesics: rise and fall of ligand biased signaling and future perspectives in the quest for the holy grail","volume":"39","author":"\u00c9 Breault","year":"2025","journal-title":"CNS Drugs"},{"issue":"2","key":"pone.0349596.ref013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2020.11.002","article-title":"Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review","volume":"77","author":"MJ Krantz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0349596.ref014","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2796.2005.01569.x","article-title":"Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness","volume":"259","author":"PE Molina","year":"2006","journal-title":"J Intern Med"},{"issue":"4","key":"pone.0349596.ref015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10877-022-00819-z","article-title":"Preoperative heart rate variability as a predictor of perioperative outcomes: a systematic review without meta-analysis","volume":"36","author":"MN Frandsen","year":"2022","journal-title":"J Clin Monit Comput"},{"issue":"6917","key":"pone.0349596.ref016","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature01321","article-title":"The inflammatory reflex","volume":"420","author":"KJ Tracey","year":"2002","journal-title":"Nature"},{"issue":"42","key":"pone.0349596.ref017","doi-asserted-by":"crossref","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling","volume":"104","author":"JW Wisler","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"pone.0349596.ref018","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.116.024482","article-title":"Long-term biased \u03b2-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy","volume":"135","author":"DM Ryba","year":"2017","journal-title":"Circulation"},{"key":"pone.0349596.ref019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased agonism: lessons from studies of opioid receptor agonists","volume":"63","author":"E Kelly","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"pone.0349596.ref020","author":"US Food and Drug Administration","year":"2020"},{"key":"pone.0349596.ref021","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.2147\/DDDT.S547901","article-title":"Effects of oliceridine versus sufentanil on hemodynamic stability in elderly hypertensive patients during laryngeal mask airway anesthesia: a randomized controlled trial","volume":"19","author":"L Chen","year":"2025","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"pone.0349596.ref022","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"MDJ Peters","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"7","key":"pone.0349596.ref023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:32:02Z","timestamp":1778866322000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349596"}},"subtitle":[],"editor":[{"given":"Yusuf Oloruntoyin","family":"Ayipo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349596","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}